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Abstract
Invasive lobular carcinomas (ILC) of breast typically demonstrate intracytoplasmic mucin. We present a unique case of 
classical type ILC with abundant extracellular mucin and strong ERBB2 (HER2/neu) expression confirmed by 
immunohistochemistry and fluorescent in situ hybridization. Dual E-cadherin/p120 immunohistochemical stain 
demonstrated complete loss of membranous E-cadherin and the presence of diffuse cytoplasmic p120 staining, 
confirming the lobular phenotype. The tumor cells showed ductal-like cytoplasmic MUC1 staining, but were negative 
for MUC2 and other mucin gene markers. In addition, studies of tissue microarrays of 80 breast carcinomas with 
mucinous differentiation revealed 4 pure mucinous carcinomas showing significantly reduced E-cadherin staining 
without redistribution of p120 into cytoplasm. The findings suggest that the presence of extracellular mucin does not 
exclude a diagnosis of lobular carcinoma, and the morphologic and molecular characteristics of lobular and ductal 
carcinomas are more complex than previously appreciated.
Introduction
Ductal carcinoma and lobular carcinoma are traditionally
considered two distinct types of mammary carcinoma
with characteristic morphology, immunohistochemical
profile, and clinical behavior. The classification of ductal
versus lobular carcinoma is routinely based on the
growth pattern and cytology of the tumor cells. E-cad-
herin immunohistochemical stain is used in cases with
equivocal morphology.
Invasive lobular carcinomas (ILCs) are characterized by
cytologically uniform cells with round nuclei and incon-
spicuous nucleoli, as well as discohesive architecture with
linear or non-linear growth pattern. A variable portion of
ILC cells show intracytoplasmic mucin secretion and
demonstrate signet-ring cell morphology. Historically,
extracellular mucin production is by default a feature of
ductal carcinoma. Lobular carcinoma has been consid-
ered a variant of mucin-secreting carcinoma with only
intracytoplasmic mucin [1-4]. In common practice, a
diagnosis of mucinous carcinoma or ductal carcinoma
with mucinous features is often made in the presence of
extracellular mucin, without immunohistochemical con-
firmation of the ductal phenotype.
The majority of classical ILCs express estrogen receptor
and progesterone receptor, but lack ERBB2 (HER2)
expression or amplification, and therefore, fall into the
"luminal" molecular class [5-12]. Rare cases of ILCs with
positive HER2 may be seen, and most represent the pleo-
morphic variant.
We report a unique case of classical ILC with abundant
extracellular mucin secretion and unusual expression of
mucin (MUC) gene product as well as HER-2 overexpres-
sion. In order to investigate whether lobular phenotype is
indeed a rare variant of extracellular mucin-producing
carcinoma of breast, we also studied tissue microarrays of
80 breast carcinomas with mucinous differentiation,
including 40 pure mucinous carcinomas and 40 carcino-
mas with mixed mucinous and non-mucinous compo-
nents.
Clinical History
A 65-year-old postmenopausal woman, who had no fam-
ily history of breast cancer, presented with a 3 cm spicu-
lated mass in the left breast on a recent mammogram.
Ultrasound-guided core biopsy performed in an outside
hospital confirmed an invasive ductal carcinoma with
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Page 2 of 7abundant mucin production. She was referred to our
institution and subsequently underwent a resection of the
tumor along with sentinel lymph node biopsy.
Materials and methods
Tissue specimens obtained from the lumpectomy were
fixed a minimum of 8 hours in 10% neutral phosphate-
buffered formalin, embedded in paraffin, and sectioned at
four microns. The paraffin-embedded sections were
stained with hematoxylin-eosin (H&E) for light micro-
scopic examination. Special stains for Mucicarmine and
Alcian-Blue were used to confirm the mucin production
and its localization.
Immunohistochemistry
Immunohistochemical studies were performed on 4-μm-
thick sections of paraffin-embedded tissue using the Ven-
tana Benchmark XT system (Tuscon, AZ) with iView
DAB (2'-diaminobenzamide) Detection Kit. The antibod-
ies with their vendors, clones, and dilutions are listed in
Table 1. For dual E-cadherin/p120 stain, cell membrane
immunostaining of E-cadherin (detected with UltraView
Universal DAB) and cell membrane p120 (detected with
UltraView Universal RED) staining were considered to be
ductal phenotype, whereas complete loss of the membra-
nous E-cadherin staining and the presence of diffuse
cytoplasmic p120 staining without membranous accentu-
ation were considered to be lobular phenotype, as
described in our previous study [13]. Estrogen receptor
(ER) and progesterone receptor (PR) were considered
positive if more than 1% of the tumor cells revealed
nuclear staining. HER2/neu was scored on a 0 to 3+ scale
using the College of American Pathologist (CAP)/Ameri-
can Society of Clinical Oncology (ASCO) criteria. Inter-
nal and external positive and negative controls
accompanied the hormone receptors and Her2 analyses.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analysis of
HER2gene was performed on a formalin-fixed block
using PathVysion dual color HER-2 DNA Probe Kit
(Vysis, Downers Grove, IL). At least 30 non-overlapping
interphase tumor cell nuclei were evaluated. In each
nucleus, the number of HER2signals and chromosome 17
centromere signals (D17Z1) were counted. The HER2/
CEP17 ratio was calculated. A ratio of greater than 2.2 is
considered to be amplified according to recent ASCO-
CAP guidelines.
Tissue Microarray
Tissue microarrays (TMAs) with threefold redundancy
were created for 40 cases of pure mucinous carcinoma
and 40 cases of carcinomas with mixed mucinous and
non-mucinous components. Three to six tissue cores
each with a core diameter of 0.6 mm punched from rep-
resentative tumor regions of each donor block were
transferred and arrayed into a new recipient paraffin
blocks using a tissue microarrayer (Beecher Instruments,
Sun Prairie, WI, USA).
Results
Histologic findings
Microscopic examination revealed a tumor with predom-
inantly solid and nested growth pattern, which inter-
vened with abundant extracellular mucinous material
(Figure 1). In the peripheral areas where minimal mucin
was present, the tumor formed infiltrating cords and sin-
gle files. The tumor cells were small to medium in size,
relatively uniform and round, with small nucleoli and
scant to moderate amount of cytoplasm. Signet-ring cells
with intracytoplasmic vacuoles were readily seen. Foci of
classical lobular carcinoma in situ were present away
from the invasive component. One of the sentinel lymph
nodes demonstrated a 3.5 mm focus of metastasis with
Table 1: Antibodies used for immunohistochemistry
Antibody Clone Dilution Source
E-cadherin ECH-6 1:100 Ventana (Tucson, AZ)
p120 98 1:200 BD Biosciences (San Diego, CA)
ER SP1 Prediluted Ventana (Tucson, AZ)
PR 1E2 Prediluted Ventana (Tucson, AZ)
c-erbB-2 CB11 Prediluted Ventana (Tucson, AZ)
Ki-67 30-9 Prediluted Ventana (Tucson, AZ)
MUC1 Ma695 1:100 Vector (Burlingame, CA)
MUC2 Ccp58 1:25 Vector (Burlingame, CA)
MUC4 1G8 1:100 Zymed (San Francisco, CA)
MUC5AC CLH2 1:100 Vector (Burlingame, CA)
MUC6 CLH5 1:25 Vector (Burlingame, CA)
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Figure 1 A case of invasive lobular carcinoma of breast with extracellular mucin. The tumor showed discohesive (A, H&E, ×100) and nested (B, 
×200) growth with abundant extracellular mucin. At the periphery, the tumor cells formed cords and single files (C, ×100). Cytologically, the tumor 
cells were small to medium in size and relatively uniform (D, ×400), with scattered signet ring cells present (D inset, arrows, ×400). A sentinel lymph 
node showed metastatic focus of uniform tumor cells (E inset, ×40) in dissociated infiltrating pattern (E, ×200). Immunohistochemical stain revealed 
complete absence of membranous E-cadherin staining (brown) and the presence of diffuse cytoplasmic p120 staining (pink); a normal duct with 
membranous staining for both E-cadherin and p120 served as an internal control (F, immunohistochemistry, ×400). Alcian Blue (G, ×200) and Muci-
carmine (H, ×200) stains highlighted both extracellular and intracellular mucin.
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without associated mucin, characteristic of metastatic
lobular carcinoma in a lymph node (Figure 1). Special
stains for Mucicarmine and Alcian Blue highlighted
extracellular as well as intracellular mucin (Figure 1).
Immunohistochemical findings
Dual E-cadherin/p120 stain was performed to character-
ize the phenotype of the tumor (Figure 2). The internal
control of the normal duct showed membranous staining
of both E-cadherin (brown) and p120 (red). The tumor
cells demonstrated complete absence of membranous E-
cadherin staining but diffuse cytoplasmic p120 staining,
unequivocally confirming the lobular phenotype.
The lobular carcinoma cells were diffusely and strongly
positive for ER, but negative for PR. Uncommonly seen in
lobular carcinomas, the tumor cells revealed an unambig-
uous diffuse 3+ HER-2 staining (Figure 2). Ki-67 stain
showed approximately 25% proliferation index.
To evaluate the expression profile of mucin in this
unusual case, a panel of immunohistochemical stains for
mucin (MUC) gene products was performed. Essentially
all the tumor cells demonstrated strong cytoplasmic
MUC1 staining (Figure 2), but were negative for MUC2,
MUC4, MUC5AC and MUC6.
FISH findings
The ratio of HER-2/neu signals to chromosome 17 cen-
tromere signals was >8.74. Since a ratio of greater than
2.2 is considered amplified, this specimen was unequivo-
cally amplified for HER2 gene (Figure 2). The average
number of HER-2 signals per cell was >12.68. The average
number of signals for the chromosome 17 centromere
was 1.45. Overall, the FISH findings were typical of a
HER2 immunohistochemical 3+ case.
TMA findings
All 40 cases of carcinoma with mixed mucinous and non-
mucinous components showed distinct membranous
stainings for both E-cadherin and p120, depicting a clear
ductal phenotype. However, 4 of the 40 cases (10%) of
pure mucinous carcinoma demonstrated significant
reduction in the membranous staining of E-cadherin
without redistribution of cytoplasmic p120 staining (Fig-
ure 3). All 4 cases that showed reduced E-cadherin stain-
ing were nuclear grade 1 and negative for HER2
immunohistochemical stain.
Discussion
Since the term lobular carcinoma was coined by Foote
and Stewart in 1941 [14], it had long been accepted that
Figure 2 Characteristics of the invasive lobular carcinoma with 
extracellular mucin. The tumor cells revealed strong cytoplasmic 
MUC1 staining (top left, immunohistochemistry, ×200), but were neg-
ative for MUC2, MUC4, MUC5AC and MUC6 (images not shown). The 
tumor cells were positive for ER (top right, ×400), negative for PR (im-
age not shown), and positive for HER-2/neu with 3+ staining (bottom 
left, ×400). FISH study confirmed the amplification of HER-2 gene (bot-
tom right, ×1,000).
Figure 3 Cases of pure mucinous carcinoma with significantly re-
duced membranous E-cadherin and p120 staining without redis-
tribution of p120 into cytoplasm (A, H&E, ×400; B, inset is a typical 
mucinous carcinoma with strong membranous E-cadherin staining, 
immunohistochemistry, ×400).
Yu et al. Diagnostic Pathology 2010, 5:36
http://www.diagnosticpathology.org/content/5/1/36
Page 5 of 7the histologic pattern of lobular carcinoma was suffi-
ciently distinct that a diagnosis could be comfortably
made on the histologic sections. In the past three
decades, the problems in reproducible diagnosis of inva-
sive lobular carcinoma had been appreciated [15-17].
While the diversity of growth patterns is a major contrib-
uting factor to the reproducibility problem, the cytologic
features of classical lobular carcinoma cells seem to have
some value in recognizing the lobular phenotype. In our
current case, the tumor growth pattern and cytomorpho-
logic features are characteristic of a classical type ILC,
even though the extracellular mucin secretion in ILCs has
almost never been documented in the literature until a
recent case report [18].
In most equivocal cases, immunohistochemical stains
can help to solve the problem. Moll et al. demonstrated
the loss of E-cadherin expression, an epithelial specific
intracellular adhesion molecule, in lobular carcinoma
[19]. The study by Dabbs et al. further indicated that the
E-cadherin catenin complex was regularly disrupted in
lobular neoplasia, manifested by the absence of E-cad-
herin in the cell membrane and redistribution of p120
catenin in the cytoplasm [20]. The absence of membra-
nous E-cadherin staining and the diffuse cytoplasmic or
punctuate paranuclear p120 staining are diagnostic of
lobular phenotype [20-22]. The complete loss of mem-
branous E-cadherin and the presence of diffuse cytoplas-
mic p120 staining pattern in our case unequivocally
confirm the lobular phenotype of the tumor.
Mucin has been classified as membrane-bound mucin,
which mediate signal transduction, and secretary mucin,
which are directly secreted into extracellular spaces [23].
Mucinous breast lesions consist of a wide spectrum from
benign fibrocystic changes to mucinous papillary lesions
and mucinous carcinomas [4,24]. Extracellular mucin
secretion is widely accepted as an indication of ductal
phenotype, including solid papillary neoplasm, ductal
carcinoma and mucinous carcinoma. In contrast, lobular
carcinoma has been considered a variant of mucin-
secreting carcinoma with only intracytoplasmic mucin
[1-4].
Our case suggests that the lobular phenotype of breast
carcinoma and the extracellular mucin secretion are not
mutually exclusive. In spite of the presence of extracellu-
lar mucin, when the characteristic discohesive growth
pattern and uniform cytology are present, a lobular carci-
noma should be considered, and E-cadherin immunohis-
tochemical stain should be performed to confirm the
phenotype.
Intriguingly, none of the 80 TMAs of breast carcinoma
with mucinous differentiation demonstrated clear immu-
nohistochemical evidence of lobular phenotype, as it did
in the current case. However, among the 80 cases, 4 of the
pure mucinous carcinomas revealed significantly reduced
membranous staining of both E-cadherin and p120, with-
out redistribution of p120 into cytoplasm. Even though
the significance of the finding is not clear at present, it
confirms that the clear-cut lobular phenotype is a rare
phenomenon in breast carcinomas with extracellular
mucin production.
In the MUC gene family, the membrane-bound mucins
include MUC1, MUC3, MUC4, among others; the secre-
tary mucins include MUC2, MUC5AC, MUC6, among
others [23]. Mucinous carcinoma of breast predomi-
nantly expresses the secretary mucins, MUC2 and MUC6
[4,24,25]. None of the ILCs and only a minority of inva-
sive ductal carcinomas (IDCs) in the previous studies
revealed MUC2 expression [24,25]. In contrast, overex-
pression of MUC1, which is present on the apical surface
of normal secretary epithelium, has been demonstrated
in the surface membrane of mucinous carcinoma cells, as
well as in the cytoplasm of IDCs and intracytoplasmic
vacuoles of ILCs [24,25].
The tumor in our case was negative for MUC2, MUC4,
MUC5AC and MUC6. However, essentially all the tumor
cells demonstrated cytoplasmic expression of MUC1,
with some of the intracytoplasmic vacuoles being posi-
tive. This MUC1 staining pattern is similar to what has
been observed in IDCs in some of the previous studies, in
contrast to the predominant pattern of intracytoplasmic
vacuoles in ILCs [24,25]; but it is similar to the study by
Rahn et al., in which approximately half of the ILCs also
showed strong cytoplasmic staining [26]. Numerous
molecular and biochemical studies have demonstrated
that MUC1 is involved in the inhibition of E-cadherin
mediated cell-cell and cell-matrix adhesion [23,26-30].
The cytoplasmic domain of MUC1 molecule has been
shown to inhibit the formation of E-cadherin - β-catenin
complex [27,29,30]. Therefore, MUC1 may play a role in
tumor invasion and metastases by disrupting cell adhe-
sions. Disruption of E-cadherin-catenin complex is char-
acteristic for lobular carcinomas, manifested as loss of E-
cadherin immunoreactivity. As a consequence, invasive
lobular carcinomas have a propensity for dissociated
growth pattern and metastasis. Hence, it is not surprising
to see overexpression of MUC1 in ILCs. However, the
association between aberrant MUC1 expression pattern
and phenotypic differentiation of breast carcinomas is
still unclear.
In addition to the extracellular mucin production,
another unusual presentation in our case is the amplifica-
tion of HER2 gene in a classical ILC. The majority of
ILCs, especially classical type, does not overexpress
HER2 protein and belongs to luminal A or B molecular
class [5-12]. In the only other case of classical ILC with
extracellular mucin secretion in the literature, the tumor
cells were negative for HER2 [18]. The four cases with
reduced E-cadherin staining in our concurrent TMA
Yu et al. Diagnostic Pathology 2010, 5:36
http://www.diagnosticpathology.org/content/5/1/36
Page 6 of 7study also showed negative HER2 expression. Our cur-
rent case has drawn attention to the overlapping morpho-
logic features as well as molecular manifestations
between IDC and ILC. The morphological heterogeneity
of breast carcinomas may, in fact, reflect the complex
molecular pathogenesis of breast tumors.
Recent molecular and IHC studies have suggested that
biomarker profile of an invasive cancer is likely more rele-
vant for treatment purposes than subtyping tumors as
ductal versus lobular. [7-10]. However, correct classifica-
tion is important for uniform diagnosis, recognizing
tumor recurrences, and understanding the biologic basis
of the disease process.
Early genomic studies revealed very little overall differ-
ence in genomic profiles between low-grade IDC and
classic ILC, implying that classic ILC might represent a
subtype of low-grade IDC [31-34]. Recent gene expres-
sion studies comparing ILCs and IDCs have identified
two subsets of ILCs with distinct transcription patterns
[5,12]. Approximately half of the ILCs differ from IDCs in
gene expression profiles ("typical" ILCs), while the
remaining ILCs closely resemble IDCs in transcription
patterns ("ductal-like" ILCs). On the other hand, a recent
study on grade- and molecular subtype-matched ILCs
and IDCs of no special type demonstrated that ILCs had
different transcriptomic profiles in the genes related to
cell-to-cell adhesion and signaling, as well as actin
cytoskeleton signaling, when compared to grade- and
molecular subtype-matched IDCs. This finding suggested
that even though ILCs and IDCs might present as a spec-
trum or form a family, there were important differences
that warrant classifying them into distinct entities [11].
In summary, we presented a case of classical type inva-
sive lobular carcinoma with abundant extracellular mucin
production, cytoplasmic MUC1 expression and unequiv-
ocal HER2 gene amplification. It brings awareness to the
facts that extracellular mucin secretion is not an exclusive
feature of ductal phenotype, and the classical morpho-
logic definition of ductal and lobular carcinomas could
sometimes be misleading. The differential expressions of
E-cadherin and p120 in ductal and lobular carcinomas
are useful tools to make the distinction in cases with
mixed or unusual morphologic features. The phenotypic
heterogeneity, including morphologic and immunohisto-
logic variables, exists in lobular and ductal carcinomas,
which may in fact reflect the molecular and genetic alter-
ations in a comprehensive evolutionary pathway. More
case observations and further studies are needed to docu-
ment the biological behavior as well as molecular profiles
associated with the phenotypic hybrids and their implica-
tions in clinical management.
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